Asia Pacific Hyaluronic Acid Market For Knee Osteoarthritis Treatment Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
USD
501.42 Million
USD
1,051.92 Million
2024
2032
 예측 기간 |
2025 –2032 |
 시장 규모(기준 연도) |
USD 501.42 Million |
 시장 규모(예측 연도) |
USD 1,051.92 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
|
아시아 태평양 무릎 골관절염 치료를 위한 히알루론산 시장 시장 세분화, 제품 유형별(단일 주사(모노상), 3회 주사 요법(트리상), 5회 주사 요법(펜타상)), 제형(가교 히알루론산 , 비가교 히알루론산), 분자량(고분자량(HMW) HA, 저분자량(LMW) HA, 중간 분자량 HA), 치료 목표(점성 보충, 항염증 및 통증 감소, 연골 보호 및 재생), 최종 사용자(병원, 정형외과 클리닉, 외래 수술 센터, 전문 통증 관리 센터), 유통 채널(직접 입찰, 소매 및 온라인 약국, 기타), 국가(중국, 인도, 일본, 한국, 호주, 인도네시아, 태국, 말레이시아, 베트남, 필리핀, 대만, 싱가포르, 뉴질랜드, 필리핀, 카자흐스탄, 브루나이 및 기타 아시아 태평양 지역) - 2032년까지의 산업 동향 및 전망
무릎 골관절염 치료를 위한 히알루론산 시장 규모
- 아시아 태평양 지역 무릎 골관절염 치료용 히알루론산 시장 규모는 2024년 기준 5억 142만 달러 로 평가됐으며, 2032년까지 10억 5,192만 달러 에 이를 것으로 예상된다.
- 2025년부터 2032년까지의 예측 기간 동안 시장은 주로 예상되는 치료법 출시에 의해 주도되어 연평균 성장률 9.8%로 성장할 것으로 예상됩니다.
- 무릎 골관절염 유병률 증가와 최소 침습 치료에 대한 선호도 증가로 히알루론산 기반 치료법에 대한 수요가 증가하고 있습니다. 또한, 점성 보충 요법의 이점에 대한 인식이 높아짐에 따라 시장 성장이 더욱 가속화되고 있습니다.
무릎 골관절염 치료를 위한 히알루론산 시장 분석
- 히알루론산은 체내, 특히 결합 조직, 피부, 그리고 관절을 윤활하는 활액에 존재하는 천연 물질입니다. 무릎 골관절염 치료에서 히알루론산은 관절 기능을 개선하고 통증을 완화하는 점성 보충제로 사용됩니다. 히알루론산을 무릎 관절에 직접 주입하면 쿠션 효과를 높이고, 운동 중 마찰을 줄이며, 연골 재생을 촉진하여 골관절염 증상 완화에 도움을 줄 수 있습니다. 이 치료는 운동 능력 회복, 삶의 질 향상, 그리고 질병 진행 지연을 목표로 합니다.
- 아시아 태평양 지역은 무릎 골관절염 치료를 위한 히알루론산 시장에서 선두 지역으로 부상하고 있는데, 이는 잘 확립된 의료 시스템과 첨단 비수술적 관절 치료 옵션의 높은 도입에 힘입은 것입니다.
- 예를 들어, 미국은 환자 인식 증가와 유리한 보상 정책에 힘입어 관절 내 히알루론산 주사의 강력한 수용을 보이고 있습니다.
- 이 지역은 골관절염 환자의 이동성과 삶의 질을 개선하는 데 중점을 두고 있으며, 이를 통해 히알루론산 기반 치료법의 혁신과 시장 확대가 지속적으로 이루어지고 있습니다.
무릎 골관절염 치료를 위한 히알루론산 시장 세분화 및 보고서 범위
|
속성 |
무릎 골관절염 치료를 위한 히알루론산 시장 주요 시장 통찰력 |
|
다루는 세그먼트 |
|
|
포함 국가 |
|
|
주요 시장 참여자 |
|
|
시장 기회 |
|
|
부가가치 데이터 정보 세트 |
Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 적용 범위, 주요 업체 등 시장 시나리오에 대한 통찰력 외에도 수입 수출 분석, 생산 능력 개요, 생산 소비 분석, 가격 추세 분석, 기후 변화 시나리오, 공급망 분석, 가치 사슬 분석, 원자재/소모품 개요, 공급업체 선택 기준, PESTLE 분석, Porter 분석 및 규제 프레임워크가 포함됩니다. |
무릎 골관절염 치료를 위한 히알루론산 시장 동향
“최소 침습적이고 표적화된 치료에 대한 선호도 증가”
- A key trend in the Asia-Pacific hyaluronic acid market for knee osteoarthritis treatment is the increasing preference for minimally invasive, targeted treatment options.
- Hyaluronic acid injections, also known as viscosupplementation, offer localized pain relief and improved joint mobility without the need for surgical intervention, making them highly attractive to both patients and clinicians
- For instance, single and multi-injection formulations tailored to patient needs are gaining traction, offering flexibility and convenience in treatment regimens
- The trend is further supported by advancements in injection techniques, improved formulation stability, and extended duration of therapeutic effects.
- Additionally, the integration of imaging technologies such as ultrasound-guided injections enhances precision and patient comfort.
- This shift towards non-surgical, effective, and patient-centric treatment options is shaping the future of knee osteoarthritis care and fueling growth in the hyaluronic acid market.
Hyaluronic Acid Market for Knee Osteoarthritis Treatment Market Dynamics
Driver
“Increasing Prevalence of Knee Osteoarthritis”
- As the Asia-Pacific population increasingly comprises older adults, the prevalence of osteoarthritis, a degenerative joint condition characterized by the breakdown of cartilage, is expected to grow significantly. This growing demographic trend is particularly alarming since osteoarthritis leads to symptoms such as chronic pain, stiffness, and decreased mobility, which can severely impact the quality of life for individuals affected. The rising incidence of osteoarthritis is prompting a surge in the demand for effective treatment solutions, as many patients are seeking alternatives to invasive surgical options. Hyaluronic acid (HA) injections have emerged as a highly favored minimally invasive treatment option that effectively alleviates symptoms by providing lubrication to the affected joint, thus enhancing joint function and mobility.
- These injections work by supplementing the naturally occurring hyaluronic acid in the synovial fluid, reducing friction between joints and promoting better shock absorption. This dual action not only helps to relieve pain but also improves overall joint health, making HA an appealing choice for both patients and healthcare providers.
For instance,
- In December 2023, NCBI stated that studies continue to illustrate the high prevalence of OA worldwide, with a greater burden among older individuals, women, some racial and ethnic groups, and individuals with lower socioeconomic status. Modifiable risk factors for OA with the strongest evidence are obesity and joint injury
- In November 2024, according an article published by Frontiers, an Indian study reported increasing KOA prevalence rates across different age groups: 19.2% for those under 50, 30.7% for those aged 50–60, 39.7% for those aged 60–70, and 54.1% for those over 70 (23). Another study revealed that both the prevalence and incidence of knee osteoarthritis significantly rise after age 55. Among individuals over 55, the average prevalence rate is 13.2%, with 9.4% for men and 18.0% for women
- The growing awareness of hyaluronic acid's benefits has contributed to its adoption among healthcare professionals and patients alike. As clinical studies and research continue to demonstrate the efficacy of hyaluronic acid in reducing pain and enhancing quality of life for those suffering from knee osteoarthritis, more healthcare providers are incorporating these treatments into their practice. This increasing acceptance, coupled with the rise in osteoarthritis cases, creates a favorable environment for market growth, driving innovation and competition among manufacturers to develop advanced formulations and delivery methods for hyaluronic acid therapies.
Opportunity
“Advancements In Hyaluronic Acid Formulations and Delivery Systems”
- Improved high-molecular-weight and cross-linked hyaluronic acid products provide longer-lasting pain relief and require fewer injections. This appeals to patients seeking effective and convenient solutions for managing their condition. Innovative delivery methods, such as hydrogels and nanoparticle systems, enhance the durability and performance of hyaluronic acid in the joint. These developments meet the rising demand from an aging population. Companies can leverage these technologies to stand out in a competitive market and attract more customers. The focus on reducing treatment frequency while improving patient outcomes strengthens the market’s growth potential. This makes the hyaluronic acid sector for knee osteoarthritis treatment a highly attractive area for investment and expansion
For instance,
- As per IBSA Institut Biochimique SA, Sanofi, Seikagaku Corporation, each company has developed unique formulations to enhance joint lubrication, pain relief, and treatment durability. These innovations focus on improved retention, cross-linking technology, and patient convenience, offering long-lasting symptom relief
- In April 2024 article by sciencedirect highlighted that hyaluronic acid-based liposomes for osteoarthritis drug delivery include surface functionalization after liposome preparation using coupling chemistry or pre-synthesized hyaluronic acid-lipid conjugates through reductive amination. These methods improve biocompatibility, enable simultaneous delivery of various drugs, and enhance control over conjugation, optimizing liposomal systems for effective arthritis treatment
- Advancements in hyaluronic acid formulations and delivery systems significantly enhance the effectiveness and convenience of knee osteoarthritis treatment. By improving product longevity and reducing the frequency of injections, these innovations cater to the growing demand for minimally invasive solutions among an aging population. Companies that embrace these technologies can strengthen their market presence, attract more patients, and capitalize on industry growth. This makes investment in hyaluronic acid-based treatments a strategic opportunity for long-term success in the evolving healthcare landscape.
Restraint/Challenge
“Cost-Related Challenges and Accessibility Concerns For Hyaluronic Acid Therapy In Knee Osteoarthritis”
- Hyaluronic acid (HA) injections for knee osteoarthritis can be prohibitively expensive, particularly when insurance plans either do not cover them fully or exclude them entirely from their benefits. This financial burden often forces patients to pay out-of-pocket, which can be a significant challenge, especially for those with limited financial resources.
- Moreover, multiple injections may be required over time, increasing the cost of treatment. As a result, patients may delay or forgo HA therapy altogether, despite its potential to alleviate pain and improve joint function. The high cost of treatment and lack of insurance coverage often limit accessibility, creating disparities in care. Addressing these financial challenges is vital for making HA therapy more accessible to a wider range of patients, ensuring that more people can benefit from this effective treatment for knee osteoarthritis.
For instance,
- In February 2024, Findings from Pain Physician indicate that Patients receiving HA injections faced significantly higher median costs, especially with multiple injections, compared to those receiving Cortico-Steroid (CS) injections or no injections. Additionally, those requiring Total Knee Arthroplasty (TKA) had higher costs with HA treatment, highlighting the financial barriers associated with this therapy
- As per Sanofi, Enovis and biovico , the high cost of Hyaluronic Acid (HA) therapy for knee osteoarthritis, such as Synvisc One (USD 232.81) and Biolevox Ha (USD 323.53), limits accessibility. Many patients struggle with affordability, especially without insurance. Lower-cost options, better coverage, and pricing reforms are essential for improving access to these treatments
- 히알루론산(HA) 주사의 높은 비용과 제한된 보험 적용 범위는 많은 무릎 골관절염 환자에게 상당한 어려움을 야기합니다. 여러 차례 주사를 맞아야 하는 등 재정적 어려움으로 인해 통증 완화 및 관절 기능 개선 효과가 입증되었음에도 불구하고 환자들은 히알루론산(HA) 치료를 미루거나 포기하는 경우가 많습니다. 접근성을 높이고 더 많은 사람들이 이 치료의 혜택을 누릴 수 있도록 하기 위해서는 이러한 비용 관련 문제를 해결하는 것이 필수적입니다. 보험 적용 범위를 확대하고 본인 부담금을 줄이면 히알루론산 치료의 접근성이 높아져 궁극적으로 무릎 골관절염 환자들에게 더 나은 치료를 제공할 수 있을 것입니다.
무릎 골관절염 치료를 위한 히알루론산 시장 시장 범위
시장은 유형, 제품 유형, 흡수 장소, 연령대, 출처, 전달 방법, 성별 및 유통 채널을 기준으로 세분화됩니다.
|
분할 |
하위 세분화 |
|
제품 유형별 |
|
|
제형에 따라 |
|
|
분자량에 따라 |
|
|
치료 목표별
|
|
|
최종 사용자별 |
|
|
유통 채널별 |
|
무릎 골관절염 치료를 위한 히알루론산 시장 지역 분석
“중국은 무릎 골관절염 치료를 위한 히알루론산 시장에서 가장 우세하고 가장 빠르게 성장하는 국가입니다.”
- 중국은 첨단 의료 인프라, 비수술적 관절 치료법의 조기 도입, 주요 시장 참여자들의 강력한 입지에 힘입어 무릎 골관절염 치료를 위한 히알루론산 시장을 선도하고 있습니다.
- 중국은 무릎 골관절염 발병률 증가, 노령 인구 증가, 관절 내 히알루론산 주사와 같은 최소 침습적 치료에 대한 선호도 증가로 인해 주요 시장 점유율을 차지하고 있습니다.
- 유리한 보상 정책, 잘 확립된 규제 프레임워크, 그리고 의료비 지출 증가는 이 지역 시장 성장에 더욱 기여하고 있습니다.
- 또한, HA 제형 및 전달 기술의 혁신과 결합된 환자 이동성 및 삶의 질 향상에 대한 집중은 아시아 태평양 전역의 시장 확장을 지속적으로 촉진하고 있습니다.
무릎 골관절염 치료를 위한 히알루론산 시장 점유율
시장 경쟁 구도는 경쟁사별 세부 정보를 제공합니다. 여기에는 회사 개요, 회사 재무 상태, 매출 창출, 시장 잠재력, 연구 개발 투자, 신규 시장 진출 계획, 아시아 태평양 지역 진출 현황, 생산 시설 및 시설, 생산 능력, 회사의 강점과 약점, 제품 출시, 제품 종류 및 범위, 응용 분야별 시장 지배력 등이 포함됩니다. 위에 제시된 데이터는 해당 회사의 시장 집중도와 관련된 내용만 포함합니다.
시장에서 활동하는 주요 시장 리더는 다음과 같습니다.
- LG화학(한국)
- Bioventus LLC(미국)
- Seikagaku Corporation (Japan)
- 사노피(프랑스)
- 아니카 테라퓨틱스(Anika Therapeutics, Inc.) (미국)
- IBSA 생화학 연구소 SA(스위스)
- 비아트리스(미국)
- 짐머 바이오멧(미국)
- 피디아 파마슈치 SpA(이탈리아)
- Ferring Pharmaceuticals (스위스)
- TRB CHEMEDICA SA(스위스)
- 항저우 싱클린 의료 제품 유한회사(중국)
- 한미약품(주)(한국)
- Virchow Biotech(인도)
- 유프라시아 파마슈티컬스(캐나다)
아시아 태평양 지역 무릎 골관절염 치료를 위한 히알루론산 시장의 최신 동향
- 2024년 7월, LG화학은 중국 골관절염 치료 시장에 진출했습니다. 이판제약(Yifan Pharmaceutical)과 협력하여 골관절염 치료제 시노비안(Synovian) 주사제를 중국 시장에 출시했습니다. 이를 통해 LG화학은 중국 시장에 진출하고 포트폴리오를 확장할 수 있었습니다.
- 2023년 5월, 유프락시아 파마슈티컬스(Eupraxia Pharmaceuticals)는 골관절염(OA) 치료를 목표로 하는 EP-104IAR의 2상 임상시험의 마지막 환자 방문을 완료했다고 발표했습니다. 회사는 2분기에 주요 데이터를 확보할 계획이며, 유의미한 통증 완화 및 환자 기능 개선과 더불어 유망한 안전성 프로파일을 입증할 것으로 기대하고 있습니다.
- 2025년 3월, IBSA는 유통업체 Lunatus와 파트너십을 맺고 사우디아라비아와 UAE에서 골관절염 치료제를 확대했습니다. 이 전략적 협력은 통증 관리 솔루션을 강화하는 것을 목표로 하며, 골관절염 환자들의 선진 치료에 대한 수요 증가에 대응하기 위해 다른 지역 국가들로까지 확대될 수 있습니다.
- 2023년 6월, 유프락시아 파마슈티컬스(Eupraxia Pharmaceuticals)는 미국 FDA가 EP-104IAR에 대해 무릎 골관절염(OA) 치료용 신속심사(Fast Track) 지정을 승인했다고 발표했습니다. 이번 지정은 개발 및 규제 검토를 신속하게 처리하여 FDA와의 협력을 더욱 원활하게 하기 위한 것입니다. 유프락시아는 2023년 2분기에 최종 데이터를 발표할 예정이며, 현재 2상 임상시험을 진행하고 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 TREATMENT TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.3 AVERAGE SELLING PRICE (ASP) ANALYSIS
4.4 MICRO AND MACRO ECONOMIC FACTORS
4.5 KEY PRICING STRATEGIES
4.6 HEALTHCARE ECONOMY
4.7 PENETRATION AND GROWTH PROSPECT MAPPING
4.8 TECHNOLOGY ROADMAP
4.9 VALUE CHAIN ANALYSIS
5 COMPANY-WISE OVERVIEW OF INTRA-ARTICULAR HYALURONIC ACID (HA) INJECTION PRODUCTS BASED ON MOLECULAR WEIGHT -
6 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, REGULATORY FRAMEWORK
6.1 NORTH AMERICA
6.2 EUROPE
6.3 ASIA-PACIFIC
6.4 MIDDLE EAST AND AFRICA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF KNEE OSTEOARTHRITIS
7.1.2 GROWING PREFERENCE FOR MINIMALLY INVASIVE AND NON-SURGICAL TREATMENT OPTIONS
7.1.3 CLINICAL VALIDATION OF HYALURONIC ACID IN OSTEOARTHRITIS TREATMENT
7.1.4 RECENT LAUNCHES OF HYALURONIC ACID FOR OSTEOARTHRITIS TREATMENT
7.2 RESTRAINTS
7.2.1 COMPETITION OF ALTERNATIVE THERAPIES FOR KNEE OSTEOARTHRITIS
7.2.2 REGULATORY CHALLENGES FACED BY THE MANUFACTURERS IN THE HYALURONIC ACID MARKET
7.3 OPPORTUNITIES
7.3.1 ADVANCEMENTS IN HYALURONIC ACID FORMULATIONS AND DELIVERY SYSTEMS
7.3.2 RAISING AWARENESS AND ACCEPTANCE OF HYALURONIC ACID FOR KNEE OSTEOARTHRITIS TREATMENT AMONG PHYSICIANS AND PATIENTS
7.3.3 THE IMPACT OF COMBINING HYALURONIC ACID WITH OTHER THERAPEUTIC OPTIONS FOR KNEE OSTEOARTHRITIS
7.4 CHALLENGES
7.4.1 COST-RELATED CHALLENGES AND ACCESSIBILITY CONCERNS FOR HYALURONIC ACID THERAPY IN KNEE OSTEOARTHRITIS
7.4.2 SHORT-TERM BENEFITS WITH LIMITED LASTING EFFICACY OF HYALURONIC ACID FOR KNEE OA
8 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 SINGLE INJECTION (MONOPHASIC)
8.3 THREE-INJECTION REGIMEN (TRIPHASIC)
8.4 FIVE-INJECTION REGIMEN (PENTAPHASIC)
9 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION
9.1 OVERVIEW
9.2 CROSS-LINKED HYALURONIC ACID
9.3 NON-CROSS-LINKED HYALURONIC ACID
10 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT
10.1 OVERVIEW
10.2 HIGH MOLECULAR WEIGHT (HMW) HA
10.3 LOW MOLECULAR WEIGHT (LMW) HA
10.4 INTERMEDIATE MOLECULAR WEIGHT HA
11 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS
11.1 OVERVIEW
11.2 VISCOSUPPLEMENTATION
11.3 ANTI-INFLAMMATORY & PAIN REDUCTION
11.4 CARTILAGE PROTECTION & REGENERATION
12 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 ORTHOPEDIC CLINICS
12.4 AMBULATORY SURGICAL CENTERS
12.5 SPECIALTY PAIN MANAGEMENT CENTERS
13 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL & ONLINE PHARMACIES
13.4 OTHERS
14 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION
14.1 ASIA-PACIFIC
14.1.1 CHINA
14.1.2 JAPAN
14.1.3 INDIA
14.1.4 SOUTH KOREA
14.1.5 AUSTRALIA
14.1.6 SINGAPORE
14.1.7 THAILAND
14.1.8 INDONESIA
14.1.9 MALAYSIA
14.1.10 TAIWAN
14.1.11 NEW ZEALAND
14.1.12 PHILIPPINES
14.1.13 VIETNAM
14.1.14 KAZAKHSTAN
14.1.15 BRUNEI
14.1.16 REST OF ASIA-PACIFIC
15 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 LG CHEM
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 BIOVENTUS
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 SEIKAGAKU CORPORATION
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 SANOFI
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 ANIKA THERAPEUTICS, INC.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 EUPRAXIA PHARMACEUTICALS
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 FIDIA FARMACEUTICI S.P.A.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 FERRING
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.9 HANGZHOU SINGCLEAN MEDICAL PRODUCTS CO.,LTD.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 HANMI PHARM.CO., LTD
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 IBSA INSTITUT BIOCHIMIQUE SA.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 TRB CHEMEDICA INTERNATIONAL SA
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENTS
17.13 VIATRIS INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 VIRCHOW BIOTECH
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 ZIMMER BIOMET
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
표 목록
TABLE 1 COMPANY PRODUCT AND ADVANCEMENT IN FORMULATION
TABLE 2 COMPANY PRODUCT AND COMBINATION THERAPY
TABLE 3 PRICE OF THE HYALURONIC ACID INJECTION
TABLE 4 COMPANY PRODUCT AND LASTING EFFICACY
TABLE 5 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC SINGLE INJECTION (MONOPHASIC) IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC THREE-INJECTION REGIMEN (TRIPHASIC) IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC FIVE-INJECTION REGIMEN (PENTAPHASIC IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC CROSS-LINKED HYALURONIC ACID IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC NON-CROSS-LINKED HYALURONIC ACID IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC HIGH MOLECULAR WEIGHT (HMW) HA IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC LOW MOLECULAR WEIGHT (LMW) HA IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC INTERMEDIATE MOLECULAR WEIGHT HA IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC VISCOSUPPLEMENTATION IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC ANTI-INFLAMMATORY & PAIN REDUCTION IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC CARTILAGE PROTECTION & REGENERATION IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC HOSPITALS IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC ORTHOPEDIC CLINICS IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC AMBULATORY SURGICAL CENTERS IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC SPECIALTY PAIN MANAGEMENT CENTERS IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC DIRECT TENDER IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC RETAIL & ONLINE PHARMACIES IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC OTHERS IN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 35 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 36 CHINA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 CHINA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 38 CHINA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 39 CHINA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 40 CHINA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 41 CHINA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 42 JAPAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 JAPAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 44 JAPAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 45 JAPAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 46 JAPAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 47 JAPAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 48 INDIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 INDIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 50 INDIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 51 INDIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 52 INDIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 53 INDIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 54 SOUTH KOREA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 SOUTH KOREA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 56 SOUTH KOREA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 57 SOUTH KOREA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 58 SOUTH KOREA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 59 SOUTH KOREA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 60 AUSTRALIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 AUSTRALIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 62 AUSTRALIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 63 AUSTRALIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 64 AUSTRALIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 65 AUSTRALIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 66 SINGAPORE HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 SINGAPORE HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 68 SINGAPORE HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 69 SINGAPORE HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 70 SINGAPORE HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 71 SINGAPORE HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 72 THAILAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 THAILAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 74 THAILAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 75 THAILAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 76 THAILAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 77 THAILAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 78 INDONESIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 INDONESIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 80 INDONESIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 81 INDONESIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 82 INDONESIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 83 INDONESIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 84 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 86 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 87 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 88 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 89 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 90 TAIWAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 91 TAIWAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 92 TAIWAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 93 TAIWAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 94 TAIWAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 95 TAIWAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 96 NEW ZEALAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 97 NEW ZEALAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 98 NEW ZEALAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 99 NEW ZEALAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 100 NEW ZEALAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 101 NEW ZEALAND HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 102 PHILIPPINES HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 PHILIPPINES HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 104 PHILIPPINES HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 105 PHILIPPINES HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 106 PHILIPPINES HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 107 PHILIPPINES HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 108 VIETNAM HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 VIETNAM HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 110 VIETNAM HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 111 VIETNAM HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 112 VIETNAM HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 113 VIETNAM HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 114 KAZAKHSTAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 KAZAKHSTAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 116 KAZAKHSTAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 117 KAZAKHSTAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 118 KAZAKHSTAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 119 KAZAKHSTAN HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 120 BRUNEI HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 BRUNEI HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 122 BRUNEI HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT, 2018-2032 (USD THOUSAND)
TABLE 123 BRUNEI HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY TREATMENT GOALS, 2018-2032 (USD THOUSAND)
TABLE 124 BRUNEI HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 125 BRUNEI HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 126 REST OF ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
그림 목록
FIGURE 1 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: SEGMENTATION
FIGURE 2 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: LIFELINE CURVE
FIGURE 7 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: MARKET END USER COVERAGE GRID
FIGURE 10 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: VENDOR SHARE ANALYSIS
FIGURE 11 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: SEGMENTATION
FIGURE 12 THREE SEGMENTS COMPRISE THE ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY PRODUCT TYPE
FIGURE 13 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 RISING PREVALENCE OF KNEE OSTEOARTHRITIS IS EXPECTED TO DRIVE THE GROWTH OF ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT FROM 2025 TO 2032
FIGURE 16 THE SINGLE INJECTION (MONOPHASIC) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT IN 2025 - 2032
FIGURE 17 DROC ANALYSIS
FIGURE 18 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY PRODUCT TYPE, 2024
FIGURE 19 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY PRODUCT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 20 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY PRODUCT TYPE, CAGR (2025-2032)
FIGURE 21 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY FORMULATION, 2024
FIGURE 23 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY FORMULATION, 2025-2032 (USD THOUSAND)
FIGURE 24 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY FORMULATION, CAGR (2025-2032)
FIGURE 25 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY FORMULATION, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY MOLECULAR WEIGHT, 2024
FIGURE 27 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY MOLECULAR WEIGHT, 2025-2032 (USD THOUSAND)
FIGURE 28 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY MOLECULAR WEIGHT, CAGR (2025-2032)
FIGURE 29 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY MOLECULAR WEIGHT, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY TREATMENT GOALS, 2024
FIGURE 31 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY TREATMENT GOALS, 2025-2032 (USD THOUSAND)
FIGURE 32 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY TREATMENT GOALS, CAGR (2025-2032)
FIGURE 33 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY TREATMENT GOALS, LIFELINE CURVE
FIGURE 34 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY END USER, 2024
FIGURE 35 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 36 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY END USER, CAGR (2025-2032)
FIGURE 37 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY END USER, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY DISTRIBUTION CHANNEL, 2024
FIGURE 39 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 40 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 41 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 ASIA-PACIFIC HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT: COMPANY SHARE 2024 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
